| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 02/07/2006 | US6994979 Drug screening for compounds that modulate the function of anti-apoptotic protein Bcl-2 to induce apoptosis; identifying antitumor agents |
| 02/07/2006 | US6994978 Human osteoclast derived cathepsin |
| 02/07/2006 | US6994977 Combining a compound to be tested, a host cell expressing a recombinant protein containing a mammalian C-C chemokine receptor 3 and a ligand for binding of ligand to such receptor, detecting the formation of a receptor-ligand complex |
| 02/07/2006 | US6994975 Expression and purification of ATM protein using vaccinia virus |
| 02/07/2006 | US6994957 Using nucleic acid |
| 02/07/2006 | US6994870 Nose and skin strip containing allergens; in situ antiinflammatory agents |
| 02/07/2006 | US6994861 Antiprotozoa agents; parasiticides; prevention abortion in mammals |
| 02/07/2006 | US6994860 Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides and protective antibodies |
| 02/07/2006 | US6994859 Biologically active, hemagglutinin from type A Clostridium botulinum and methods of use |
| 02/07/2006 | US6994858 Infecting the mixed cellular compositions with reovirus which selectively lyse the ras-mediated neoplastic cells in the mixed composition |
| 02/07/2006 | US6994857 A Therapeutic protein (e.g., a polypeptide, antibody, or peptide, or fragments and variants) fused to albumin, is sufficient to prolong the shelf-lilfe of therapeutic protein |
| 02/07/2006 | US6994856 ErbB4 receptor-specific neuregulin related ligands and uses therefor |
| 02/07/2006 | US6994855 S. aureus fibrinogen binding protein gene |
| 02/07/2006 | US6994854 Protective epitopes of adenyl cyclase-haemolysin (AC-Hly), their application to the treatment or to the prevention of bordetella infections |
| 02/07/2006 | US6994853 administering to a cancer patient in a time-staggered manner: autologous or allogeneic tumor cells of the same tumor type each treated to prevent their survival after reinfusion; and intact bispecific and/or trispecific antibodies |
| 02/07/2006 | US6994852 Inhibition of angiogenesis by antibodies against high molecular weight kininogen domain 5 |
| 02/07/2006 | US6994851 cytotoxic T-lymphocyte (CTL) response; comprises placing a physiologically-acceptable, antigen-containing composition in a reservoir having a pump for delivering the composition at a defined rate through a transmission line |
| 02/07/2006 | US6994847 Stabilized interferon compositions |
| 02/07/2006 | US6994840 Kit for radiolabeling ligands with yttrium-90 |
| 02/07/2006 | CA2026147C Cytotoxic agents comprising maytansinoids and their therapeutic use |
| 02/02/2006 | WO2006012641A2 Methods for detecting and treating autoimmune disorders |
| 02/02/2006 | WO2006012621A2 Compositions and methods for regulating the alternative pathway of complement |
| 02/02/2006 | WO2006012616A2 Therapeutic use of anti-tf-antigen antibody |
| 02/02/2006 | WO2006012539A1 Contraceptives based on sp22 and sp22 antibodies |
| 02/02/2006 | WO2006012508A2 Method of treating sjögren's syndrome |
| 02/02/2006 | WO2006012416A2 Specific inhibition of autoimmunity and diseases associated with autoantigens |
| 02/02/2006 | WO2006012359A2 Methods for inducing the differentiation of blood monocytes into functional dendritic cells |
| 02/02/2006 | WO2006012092A2 Safer attenuated virus vaccines with missing or diminished latency of infection |
| 02/02/2006 | WO2006010834A1 Non-integrative and non-replicative lentivirus, preparation and uses thereof |
| 02/02/2006 | WO2006010603A1 Use of llt1 and/or cd161 for modulating the activity of cells of the immune system |
| 02/02/2006 | WO2006010514A2 Diagnostics and therapeutics for diseases associated with dual specificity mitogen-activated protein kinase kinase 5 (map2k5) |
| 02/02/2006 | WO2006010498A2 Diagnostics and therapeutics for diseases associated with methionine aminopeptidase 2 (metap2) |
| 02/02/2006 | WO2006010496A1 Diagnostics and therapeutics for diseases associated with dipeptidase 1 (dpep1) |
| 02/02/2006 | WO2006010493A1 Diagnostics and therapeutics for diseases associated with ethanolamine kinase 1 (ek11) |
| 02/02/2006 | WO2005117977A3 Tissue-specific imaging and therapeutic agents targeting proteins expressed on lung endothelial cell surface |
| 02/02/2006 | WO2005115447A3 Human anti-cancer immunotherapy |
| 02/02/2006 | WO2005099752A3 Antigen delivery vectors and constructs |
| 02/02/2006 | WO2005090966A3 Diagnostics and therapeutics for diseases associated with peroxisome proliferator activated receptor delta (ppard) |
| 02/02/2006 | WO2005068639A3 Particle-induced ghrelin immune response |
| 02/02/2006 | WO2005067543A3 Murine calicivirus |
| 02/02/2006 | WO2005049635A3 Human monoclonal antibody having fat-reducing effect |
| 02/02/2006 | WO2005046602A3 Vegf receptor antagonists |
| 02/02/2006 | WO2005004809A3 Multivalent carriers of bi-specific antibodies |
| 02/02/2006 | WO2005001038A3 Recombinant anti-cd30 antibodies and uses thereof |
| 02/02/2006 | WO2004100877A3 Vaccine accelerator factor (vaf) for poultry |
| 02/02/2006 | WO2003102166A3 Novel flavivirus antigens |
| 02/02/2006 | WO2003096967A3 Dna vaccines encoding heat shock proteins |
| 02/02/2006 | WO2003093298A3 Immunogenic peptides |
| 02/02/2006 | US20060026700 Tissue specific genes and gene clusters |
| 02/02/2006 | US20060026698 Transgenic transchromosomal rodents for making human antibodies |
| 02/02/2006 | US20060025576 Multivalent antibodies and uses therefor |
| 02/02/2006 | US20060025575 Hybridoma cell line producing monoclonal antibodies to bind to, to detect and qualitatively and quantitatively measure the presence of epitopes of prion proteins; neurodegenerative diseases of the central nervous system |
| 02/02/2006 | US20060025572 Mammalian cell surface antigens; related reagents |
| 02/02/2006 | US20060025362 Guanylate binding protein (GBP-1) as inhibitor of cell proliferation and molecular marker for the determination of the stage of cellular differentiation |
| 02/02/2006 | US20060025344 Ghrelin receptor inverse agonists for regulation of feeding behaviors |
| 02/02/2006 | US20060025341 Isolated polynucleotide encoding inhibin-related proteins for treating cancer of epithelial, testicular, ovarian, prostate; biodrug protein; activin binding activity; hormone inhibitor; muscle regeneration |
| 02/02/2006 | US20060025331 Administering anti-Flt4 antibody or an anti-VEGF-C antibody that inhibits binding between Flt4 ligand protein and Flt4 expressed in cells to treat breast cancer characterized by endothelial cells that express Flt4 tyrosine kinase |
| 02/02/2006 | US20060024800 Method of modulating the activity of functional immune molecules |
| 02/02/2006 | US20060024795 Interferon-Like molecules and uses thereof |
| 02/02/2006 | US20060024772 Parathyroid hormone antibodies and related methods |
| 02/02/2006 | US20060024754 Methods and compositions for using MHC class II invariant chain polypeptide as a receptor for macrophage migration inhibitory factor |
| 02/02/2006 | US20060024742 Immunogenic polypeptide of given sequence; diagnosis or treatment of conditions resulting from gene over-expression |
| 02/02/2006 | US20060024683 Transcription factor of MHC class II genes, substances capable of inhibiting this transcription factor and medical uses of these substances |
| 02/02/2006 | US20060024670 Influenza virus vaccine composition and methods of use |
| 02/02/2006 | US20060024668 Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics |
| 02/02/2006 | US20060024666 Humanized antibodies against the venezuelan equine encephalitis virus |
| 02/02/2006 | US20060024379 Protein microspheres having injectable properties at high concentrations |
| 02/02/2006 | US20060024346 Stabilization of biologically active proteins with mixtures of polysaccharides and amino acid based compounds |
| 02/02/2006 | US20060024334 Immunotherapeutic methods and systems |
| 02/02/2006 | US20060024333 Use of parasitic biological agents for prevention and control of allergic and other IgE-mediated disorders |
| 02/02/2006 | US20060024332 Recombinant ESAT-6:CFP-10 fusion protein useful for specific diagnosis of tuberculosis |
| 02/02/2006 | US20060024331 Toxin compounds with enhanced membrane translocation characteristics |
| 02/02/2006 | US20060024330 Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors |
| 02/02/2006 | US20060024329 Recombinant live vaccine based on canine herpesvirus, in particular against Carre's disease, rabies or the parainfluenza virus type 2. |
| 02/02/2006 | US20060024324 Glutamate-rich protein (GLURP) genetically coupled to plasmodium falciparum merozoite surface protein 3 (MSP3) for use as tool in preventing malarial infection; Antimalarial agents; parasiticides |
| 02/02/2006 | US20060024323 Active immunization using a siderophore receptor protein |
| 02/02/2006 | US20060024322 Novel prophylactics/remedies for immunopathy |
| 02/02/2006 | US20060024321 chemokines; open reading frames; long terminal repeats; site directed mutagenesis; antibodies |
| 02/02/2006 | US20060024320 Attenuated pestiviruses |
| 02/02/2006 | US20060024319 determining whether a mouse is infected with murine norovirus-1 by determining presence, absence or quantity of antibody against MNV-1 a sample of a mouse; the antibody binds to MNV-1 deposited as American Type Culture Collection (ATCC) Deposit No. PTA-5935 or to a polypeptide encoded by it |
| 02/02/2006 | US20060024318 Vaccination with immuno-isolated cells producing an immunomodulator |
| 02/02/2006 | US20060024317 Chemical linkers and conjugates thereof |
| 02/02/2006 | US20060024316 Prostatic cancer vaccine |
| 02/02/2006 | US20060024315 Vascular targets for detecting, imaging and treating neoplasia or neovasculature |
| 02/02/2006 | US20060024314 Antibodies and cyclic peptides which bind CEA (carcinoembryonic antigens) and their use as cancer therapeutics |
| 02/02/2006 | US20060024313 Agents that disrupt dimer formation in DPP-IV family of prolyl dipeptidases |
| 02/02/2006 | US20060024312 Methods for enhancing learning and memory |
| 02/02/2006 | US20060024311 Administering anti-TK1 antibody conjugated to cytotoxic agent consisting of pokeweed antiviral protein (PAP), ricin, abrin, gelonin, saporin, and alpha-sarcin; detecting and diagnosing viral infections |
| 02/02/2006 | US20060024310 Methods of treating TNFalpha-mediated tissue injury using anti-TNF antibodies and peptides |
| 02/02/2006 | US20060024309 administering vascular endothelial growth factor (VEGF) antagonists such as VEGF fusion protein traps, nucleotides, antisense agents, lipids or carbohydrates, for decreased serum glucose levels, improved glucose tolerance, and/or improved glycemic control; antidiabetic agents |
| 02/02/2006 | US20060024308 High affinity anti-TNF-alpha antibodies and method |
| 02/02/2006 | US20060024307 For treatment and prevention of acute and chronic infectious diseases, mostly of viral etiology, and for producing an immunomodulating effect; comprising a homeopathically potentised form of monoclonal, polyclonal, or natural antibody to gamma interferon, does not suppress the activity of the interferon |
| 02/02/2006 | US20060024306 Methods of treating and preventing colitis involving il-13 and nk-t cells |
| 02/02/2006 | US20060024305 Camp-regulated phosphoprotein for diagnostic and therapeutic use in neurodegenerative diseases |
| 02/02/2006 | US20060024304 Immunoglobulins comprising predominantly a Man5GlcNAc2 glycoform |
| 02/02/2006 | US20060024303 Targeting and prolonging association of drugs to the luminal surface of the pulmonary vascular endothelial cells |
| 02/02/2006 | US20060024302 Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same |
| 02/02/2006 | US20060024301 Prostate-specific polypeptides and fusion polypeptides thereof |
| 02/02/2006 | US20060024300 Immunoglobulin variants and uses thereof |
| 02/02/2006 | US20060024299 Human osteoclast derived cathepsin |